Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19

ABBV‐47D11 is a neutralizing monoclonal antibody that targets a mutationally conserved hydrophobic pocket distal to the ACE2 binding site of SARS‐CoV‐2. This first‐in‐human safety, pharmacokinetics, and antiviral pharmacodynamic assessment in patients with COVID‐19 provide an initial evaluation of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shebley, Mohamad, Wang, Stanley, Ali, Izna, Krishnan, Preethi, Tripathi, Rakesh, Reardon, Joseph M., Cafardi, John, Rahav, Galia, Caraco, Yoseph, Slim, Jihad, Al Akhrass, Fadi, Yu, Mengjia, Hu, Yiran, Ferreira, Rosa De Abreu, Alami, Negar N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764278/
https://www.ncbi.nlm.nih.gov/pubmed/36537346
http://dx.doi.org/10.1002/prp2.1036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764278/
https://www.ncbi.nlm.nih.gov/pubmed/36537346
http://dx.doi.org/10.1002/prp2.1036

Ejemplares similares